SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Furosemide Injection Formulation

Manufacturer or supplier’s details
Company name of supplier: MSD
Address: 2000 Galloping Hill Road
Kenilworth - New Jersey - U.S.A. 07033
Telephone: 908-740-4000
Emergency telephone: 1-908-423-6000
E-mail address: EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use: Veterinary product

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification
Specific target organ toxicity - repeated exposure: Category 1 (Kidney, Liver)

GHS label elements
Hazard pictograms: ⚠

Signal Word: Danger

Hazard Statements: H372 Causes damage to organs (Kidney, Liver) through prolonged or repeated exposure.

Precautionary Statements: Prevention:
P260 Do not breathe mist or vapors.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.

Response:
P314 Get medical advice/ attention if you feel unwell.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture: Mixture

Components
SAFETY DATA SHEET

Furosemide Injection Formulation

SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Get medical attention if symptoms occur.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: Causes damage to organs through prolonged or repeated exposure.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during fire fighting: Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Nitrogen oxides (NOx)
Carbon oxides
Sulfur oxides
Chlorine compounds

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

Special protective equipment for fire-fighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES
### PERSONAL PRECAUTIONS, PROTECTIVE EQUIPMENT AND EMERGENCY PROCEDURES

- Use personal protective equipment.
- Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

### ENVIRONMENTAL PRECAUTIONS

- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Prevent spreading over a wide area (e.g., by containment or oil barriers).
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

### METHODS AND MATERIALS FOR CONTAINMENT AND CLEANING UP

- Soak up with inert absorbent material.
- For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
- Clean up remaining materials from spill with suitable absorbent.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

#### TECHNICAL MEASURES

- See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

#### LOCAL/TOTAL VENTILATION

- Use only with adequate ventilation.

#### ADVICE ON SAFE HANDLING

- Do not breathe mist or vapors.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Wash skin thoroughly after handling.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Do not eat, drink or smoke when using this product.
- Take care to prevent spills, waste and minimize release to the environment.

#### HYGIENE MEASURES

- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
- When using do not eat, drink or smoke.
- Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

#### CONDITIONS FOR SAFE STORAGE

- Keep in properly labeled containers.
- Store in accordance with the particular national regulations.
SAFETY DATA SHEET

Furosemide Injection Formulation

Materials to avoid:

Do not store with the following product types:
- Strong oxidizing agents
- Organic peroxides
- Explosives
- Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Furosemide</td>
<td>54-31-9</td>
<td>TWA</td>
<td>200 µg/m³ Internal</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>OEB 2 (≥100 - 1000 µg/m³) Internal</td>
<td></td>
</tr>
</tbody>
</table>

Engineering measures:
Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., dripless quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection:
If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type: Particulates type
Hand protection Material: Chemical-resistant gloves

Eye protection:
Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: Aqueous solution
Color: yellow
Odor: No data available
Odor Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
## SECTION 10. STABILITY AND REACTIVITY

<table>
<thead>
<tr>
<th>Property</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reactivity</td>
<td>Not classified as a reactivity hazard.</td>
</tr>
<tr>
<td>Chemical stability</td>
<td>Stable under normal conditions.</td>
</tr>
<tr>
<td>Possibility of hazardous reactions</td>
<td>Can react with strong oxidizing agents.</td>
</tr>
<tr>
<td>Conditions to avoid</td>
<td>None known.</td>
</tr>
<tr>
<td>Incompatible materials</td>
<td>Oxidizing agents</td>
</tr>
<tr>
<td>Hazardous decomposition</td>
<td>No hazardous decomposition products are known.</td>
</tr>
</tbody>
</table>
SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity: Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:
Furosemide:
Acute oral toxicity: LD50 (Rat): 2,600 mg/kg
LD50 (Dog): 2,000 mg/kg
LD50 (Rabbit): 800 mg/kg

Acute toxicity (other routes of administration): LD0 (Humans): 6 - 29 mg/kg
Application Route: Intravenous
LD50 (Rat): 800 mg/kg
Application Route: Intravenous

Skin corrosion/irritation
Not classified based on available information.

Serious eye damage/eye irritation
Not classified based on available information.

Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Germ cell mutagenicity
Not classified based on available information.

Components:
Furosemide:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: In vitro mammalian cell gene mutation test  
Test system: mouse lymphoma cells  
Result: positive

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Test system: mammalian liver cells  
Result: negative

Test Type: Chromosome aberration test in vitro  
Test system: Chinese hamster ovary cells  
Result: positive

Test Type: In vitro sister chromatid exchange assay in mammalian cells  
Test system: Chinese hamster cells  
Result: negative

Genotoxicity in vivo:
Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Chinese hamster  
Application Route: Ingestion  
Result: negative

Carcinogenicity
Not classified based on available information.

Components:

Furosemide:
Species: Rat  
Application Route: Ingestion  
Exposure time: 104 weeks  
LOAEL: 16 mg/kg body weight  
Result: equivocal

Species: Mouse  
Application Route: Ingestion  
Exposure time: 2 Years  
LOAEL: 91 mg/kg body weight  
Result: positive

Reproductive toxicity
Not classified based on available information.

Components:

Furosemide:
Effects on fertility:
Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
General Toxicity Parent: NOAEL: 90 mg/kg body weight
Result: No effects on reproduction parameters.

Test Type: One-generation reproduction toxicity study
Species: Mouse
Application Route: Ingestion
General Toxicity Parent: NOAEL: 200 mg/kg body weight
Result: No effects on reproduction parameters.

Effects on fetal development:
Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
General Toxicity Maternal: LOAEL: 50 mg/kg body weight
Developmental Toxicity: NOAEL: 300 mg/kg body weight
Result: No embryotoxic effects., No teratogenic effects.

Test Type: Fertility/early embryonic development
Species: Mouse
Application Route: Ingestion
General Toxicity Maternal: LOAEL: 25 mg/kg body weight
Result: Maternal toxicity observed., Fetal effects.

Test Type: Fertility/early embryonic development
Species: Rabbit
Application Route: Ingestion
General Toxicity Maternal: LOAEL: <= 12 mg/kg body weight
Developmental Toxicity: LOAEL: 12.5 mg/kg body weight
Result: Maternal toxicity observed., Reduced number of viable fetuses.

Test Type: Fertility/early embryonic development
Species: Rabbit
Application Route: Ingestion
General Toxicity Maternal: LOAEL: 15 mg/kg body weight
Result: Maternal toxicity observed., No effects on fetal development.

**STOT-single exposure**
Not classified based on available information.

**STOT-repeated exposure**
Causes damage to organs (Kidney, Liver) through prolonged or repeated exposure.

**Components:**

**Furosemide:**
Routes of exposure: Ingestion
Target Organs: Kidney
Assessment: Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less.
Repeated dose toxicity

Components:

Furosemide:
Species: Dog
NOAEL: 4 mg/kg
LOAEL: 8 mg/kg
Application Route: Ingestion
Exposure time: 12 Months
Target Organs: Kidney
Symptoms: Blood disorders
Remarks: Significant toxicity observed in testing

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Furosemide:
Inhalation: Remarks: May be harmful if inhaled.
Skin contact: Remarks: May irritate skin.
Eye contact: Remarks: May cause eye irritation.
Ingestion: Symptoms: Kidney disorders, Headache, electrolyte imbalance, dry mouth, hearing loss, Irregular cardiac activity, Gastrointestinal disturbance, hypotension

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Furosemide:
Toxicity to fish: LC50: 500 mg/l
Exposure time: 96 h

Persistence and degradability
No data available

Bioaccumulative potential

Components:

Furosemide:
Partition coefficient: n-octanol/water: log Pow: 2.03
Mobility in soil
No data available

Other adverse effects
No data available
SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations
UNRTDG
Not regulated as a dangerous good
IATA-DGR
Not regulated as a dangerous good
IMDG-Code
Not regulated as a dangerous good
Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation
NOM-002-SCT
Not regulated as a dangerous good

Special precautions for user
Not applicable

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture
Federal Law for the control of chemical precursors, essential chemical products and machinery for producing capsules, tablets and pills.
Not applicable

The ingredients of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

Revision Date: 10.10.2020

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.